longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

13404

13404
----

LongbridgeAI

HK Midday: HSI up 1.22%; Innovator Drug Stocks Surge, Everest Medicines Soars Nearly 60%

Market Pulse
Aug 20, 2026 at 06:19 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

HSI gains 1.22% to 25,807 pts. Innovator drug stocks rally across the board — Everest Medicines skyrockets over 58%, CSPC Pharma up 13%+. Kuaishou tumbles 10%+ post-results. Gold stocks advance as spot gold breaks US$4,500.

Hong Kong equities extended gains into the afternoon session on August 20, with all three major indexes advancing. As of press time, the Hang Seng Index rose 1.22%, or 312.22 points, to 25,807.29; the Hang Seng Tech Index climbed 1.29% to 4,742.55; and the HSCEI added 1.43% to 8,592.33. Innovator drug stocks erupted in a broad-based rally, gold miners advanced in unison, while tech names traded mixed with Kuaishou slumping over 10% post-results.

Innovator Drug Stocks Erupt; Everest Medicines Rockets Nearly 60%

As of press time, Everest Medicines (01952.HK) soared more than 58% to HK$37.72; CSPC Pharmaceutical Group (01177.HK) surged over 13% to HK$5.42; Sino Biopharmaceutical (01093.HK) jumped nearly 10% to HK$9.55; WuXi Biologics (02269.HK) advanced over 4% to HK$50.00; WuXi AppTec (02359.HK) and BeiGene (06160.HK) each gained about 3%, with both notching fresh all-time highs.

On the catalyst front, a breakthrough in Moderna's mRNA vaccine development lifted global innovator drug sentiment. Several pharmaceutical firms delivered robust interim results, with Sino Biopharmaceutical and CSPC Pharma attracting inflows post-earnings. Everest Medicines' pipeline progress has fueled market optimism around its commercialisation prospects.

Tech Names Mixed; Kuaishou Tumbles Over 10% Post-Results

As of press time, Kuaishou-W (01024.HK) slumped over 10% to HK$34.00 on turnover of nearly HK$6.7 billion; Alibaba-W (09988.HK) rose nearly 3% to HK$127.7; Baidu-SW (09888.HK) gained over 3% to HK$93.05; JD.com-SW (09618.HK) added about 3% to HK$116.1; Tencent Holdings (00700.HK) edged up nearly 2% to HK$455.6.

Kuaishou's earlier earnings release missed market expectations, prompting multiple major banks to slash target prices. The stock's short-selling ratio spiked to as high as 30.9% during the half-day session. Zhang Zhiwei of Pinpoint Capital warned that Kuaishou shares may not have found a bottom yet. Meanwhile, all eyes are on Alibaba's upcoming results, seen as a key variable for the market's next move.

Gold Miners Advance as Spot Gold Breaks US$4,500

As of press time, Lingbao Gold (03330.HK) surged nearly 8% to HK$23.76; Zijin Mining Group (02899.HK) jumped over 6% to HK$37.00; Chifeng Gold (06693.HK) gained over 5% to HK$41.32.

The US Treasury's announcement of expanded long-dated bond buybacks drove Treasury yields lower, sending spot gold past US$4,500 to a two-month high. Analysts noted that gold has broken out of its consolidation range, with a target zone of US$4,600–4,800 in sight.

In other movers, Nine Dragons Paper (02689.HK) issued a positive profit alert forecasting up to a doubling of full-year earnings, yet the stock still tumbled over 12% to HK$6.96, extending its losing streak to four sessions. Bank of East Asia (00023.HK) hiked its interim dividend by 18%, sending shares up over 4% to HK$16.98. AAC Technologies (02018.HK) posted a 2.9% rise in half-year profit, but its stock slid over 6% to HK$38.96.

Login to unlock2,450characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Related Stocks

EVEREST MED

EVEREST MED

HK01952

-6.09%

SBP GROUP

SBP GROUP

HK01177

-4.20%

CSPC PHARMA

CSPC PHARMA

HK01093

-0.68%